Management of adult acute lymphoblastic leukemia

Moving toward a risk-adapted approach

Amit K. Verma, Wendy Stock

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

The vast majority of adults with acute lymphoblastic leukemia (ALL) now achieve remission with current intensive chemotherapy regimens. Nevertheless, most adults with ALL will eventually relapse and die of their disease. Specific clinical and molecular-cytogenetic prognostic factors have been identified that are beginning to provide insights for the development of risk-adapted management strategies that appear to improve survival for several high-risk patient groups, including those with mature B-cell ALL and B-lineage ALL patients with a Philadelphia chromosome. We review standard and some recently described prognostic factors in adult ALL, describe current therapy based on a risk-adapted approach, and look toward the future with a brief discussion of novel, targeted treatments that could be incorporated into postremission strategies to improve survival for adults with ALL.

Original languageEnglish (US)
Pages (from-to)14-20
Number of pages7
JournalCurrent Opinion in Oncology
Volume13
Issue number1
DOIs
StatePublished - 2001
Externally publishedYes

Fingerprint

Precursor Cell Lymphoblastic Leukemia-Lymphoma
Philadelphia Chromosome
Survival
Risk Management
Cytogenetics
B-Lymphocytes
Recurrence
Drug Therapy
Therapeutics

ASJC Scopus subject areas

  • Cancer Research

Cite this

Management of adult acute lymphoblastic leukemia : Moving toward a risk-adapted approach. / Verma, Amit K.; Stock, Wendy.

In: Current Opinion in Oncology, Vol. 13, No. 1, 2001, p. 14-20.

Research output: Contribution to journalArticle

@article{53b12330732c4977866de5dca8fdbac0,
title = "Management of adult acute lymphoblastic leukemia: Moving toward a risk-adapted approach",
abstract = "The vast majority of adults with acute lymphoblastic leukemia (ALL) now achieve remission with current intensive chemotherapy regimens. Nevertheless, most adults with ALL will eventually relapse and die of their disease. Specific clinical and molecular-cytogenetic prognostic factors have been identified that are beginning to provide insights for the development of risk-adapted management strategies that appear to improve survival for several high-risk patient groups, including those with mature B-cell ALL and B-lineage ALL patients with a Philadelphia chromosome. We review standard and some recently described prognostic factors in adult ALL, describe current therapy based on a risk-adapted approach, and look toward the future with a brief discussion of novel, targeted treatments that could be incorporated into postremission strategies to improve survival for adults with ALL.",
author = "Verma, {Amit K.} and Wendy Stock",
year = "2001",
doi = "10.1097/00001622-200101000-00004",
language = "English (US)",
volume = "13",
pages = "14--20",
journal = "Current Opinion in Oncology",
issn = "1040-8746",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Management of adult acute lymphoblastic leukemia

T2 - Moving toward a risk-adapted approach

AU - Verma, Amit K.

AU - Stock, Wendy

PY - 2001

Y1 - 2001

N2 - The vast majority of adults with acute lymphoblastic leukemia (ALL) now achieve remission with current intensive chemotherapy regimens. Nevertheless, most adults with ALL will eventually relapse and die of their disease. Specific clinical and molecular-cytogenetic prognostic factors have been identified that are beginning to provide insights for the development of risk-adapted management strategies that appear to improve survival for several high-risk patient groups, including those with mature B-cell ALL and B-lineage ALL patients with a Philadelphia chromosome. We review standard and some recently described prognostic factors in adult ALL, describe current therapy based on a risk-adapted approach, and look toward the future with a brief discussion of novel, targeted treatments that could be incorporated into postremission strategies to improve survival for adults with ALL.

AB - The vast majority of adults with acute lymphoblastic leukemia (ALL) now achieve remission with current intensive chemotherapy regimens. Nevertheless, most adults with ALL will eventually relapse and die of their disease. Specific clinical and molecular-cytogenetic prognostic factors have been identified that are beginning to provide insights for the development of risk-adapted management strategies that appear to improve survival for several high-risk patient groups, including those with mature B-cell ALL and B-lineage ALL patients with a Philadelphia chromosome. We review standard and some recently described prognostic factors in adult ALL, describe current therapy based on a risk-adapted approach, and look toward the future with a brief discussion of novel, targeted treatments that could be incorporated into postremission strategies to improve survival for adults with ALL.

UR - http://www.scopus.com/inward/record.url?scp=0035173425&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035173425&partnerID=8YFLogxK

U2 - 10.1097/00001622-200101000-00004

DO - 10.1097/00001622-200101000-00004

M3 - Article

VL - 13

SP - 14

EP - 20

JO - Current Opinion in Oncology

JF - Current Opinion in Oncology

SN - 1040-8746

IS - 1

ER -